Fundraising Fox
Neo Kuma Ventures
Venture capitalLondon · Pre-Seed–Series A · 7 people tracked
Find your way into Neo Kuma Ventures
Sign up to see every warm intro you have to Neo Kuma Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neo Kuma Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
The fund believes psychedelic compounds represent a paradigm shift in mental health treatment, with FDA breakthrough designations validating their potential to address root causes of mental illness affecting over 350 million patients globally. Investment focuses on the intersection of expanding clinical evidence, regulatory liberalization, and ecosystem development. The firm targets early-stage, science-driven ventures across compounds, clinic operations, digital therapeutics, and care platforms, leveraging expertise in biotech, pharmaceutical development, and policy advocacy to support founders from inception to scale.
Source: firm website, verified Aug 6, 2026.
Team · 7 people
from the firm's website & public directories
A biotech and life sciences investor with over 15 years in venture capital, private equity, operations, and deal execution. Recognized among the most influential women in psychedelics by Business Insider, with education from Oxford University and NYU School of Law.
An executive coach and co-founder and chair of Andela, where she raised over $181M and grew the organization to over 2,000 employees with a $50M run rate within six years. Prior experience includes roles at the MasterCard Foundation and the Clinton Global Initiative.
An experienced investor in public and private companies across credit and equity markets with broad expertise in technology, medical devices, pharmaceuticals, and biologics. Career includes senior roles at Blackrock and boutique investment firms in London and Asia.
Co-founder and general partner at Outsized Ventures focused on human health. Previously a healthcare and life sciences investor at White Cloud and a corporate lawyer at Slaughter and May.
A venture partner with healthcare investment and pharmaceutical expertise, holding a DPhil in Chemical Biology from Oxford University and a master's degree in chemistry from Warwick University.
A medical biologist and neuroscientist holding distinguished academic positions including Head of the Department of Molecular Neurobiology and Rector Magnificus at Utrecht University, and Director of the Rudolf Magnus Institute for Neuroscience.
What they invest in
from 3 of 3 portfolio companiesDigital Health ×3Mental Health ×2Wellness & Fitness ×2Healthtech ×1HR Tech ×1Medical Devices ×1
HQs:United Kingdom×1
Investments · 3 tracked
founders shown can be your intro pathBy year:2023 · 12021 · 23 dated
Journey Clinical provides ketamine-assisted psychotherapy (KAP) for depression, anxiety, and PTSD, partnering patients with licensed therapists and medical teams while coordinating with major insurance providers.
Digital HealthMedical DevicesMental Health
Jonathan Sabbagh(Founder)inMyriam Barthes(Founder)in
Co-investorsAble PartnersAlleyCorpCoalition OperatorsFifty YearsFJ LabsGaingels+9 more
__Twitter.png)
Syndi (HealthKey) operates a platform that gives organisations access to around 75 vetted healthcare providers, letting employers and insurers offer employees and customers services like therapy, physiotherapy, nutrition and at-home testing.
Digital HealthHealthtechHR TechWellness & FitnessLondon, GB
Benjamin Lakey(CEO)inJorge Alexander(Founding CTO)in
Co-investorsEntrepreneur FirstPlug and Play VenturesFounders FactoryInnovate UKREMUS Capital
Wavepaths develops adaptive therapeutic music designed to support mental health and wellness practitioners in their sessions.
Digital HealthMental HealthWellness & Fitness
Mendel Kaelen(Founder & CEO)in
Co-investorsMITONReflex CapitalTabula Rasa VenturesEmpath VenturesLIONHEART VENTURESPalo Santo VC
Frequently asked questions
- What stage does Neo Kuma Ventures invest at?
- Neo Kuma Ventures invests at the Pre-Seed, Series A stages.
- What is Neo Kuma Ventures's typical check size?
- Neo Kuma Ventures typically writes checks of $195K – $1.3M.
- What sectors does Neo Kuma Ventures focus on?
- Neo Kuma Ventures focuses on Biotech, Digital Health, Healthtech, Mental Health.
- Where is Neo Kuma Ventures located?
- Neo Kuma Ventures is headquartered in London, GB.
Media · Podcasts & interviews
featuring the teamAdvancements in psychedelic therapy - Expert Talk with Sean McLintock , Neo Kuma Ventures
Kalkine Media · Sean McLintock
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
.png)
Better Ventures is an early-stage venture capital firm founded in 2011 that backs mission-driven technology companies building what it calls the 'Better Economy,' where people and the planet thrive.
Mystic Ventures is an early-stage investor backing teams in psychedelic medicine and consciousness expansion, focusing on companies at the intersection of biotechnology, AI, and longevity.